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1. Introduction 2. Materials 
The demand for completion of all transformations 
in the Merrifield synthesis of peptides i widely 
accepted as the categorical imperative of the method, 
which in the future aims at well defined synthetic 
proteins [2]. Continually performed analytical monito- 
ring of all steps [3] is essential, since deviations of 
<1% from quantitative r actions seriously endanger 
the success of an extended peptide synthesis (> I0 
amino acid residues) on polymer support by formation 
of false sequences [4]. 
Nevertheless, besides our methodical nd analytical 
improvements [5] of the Merrifield technique [6] 
there remains the question for final uniformity of 
the peptide sequence synthetized on insoluble polymers. 
To answer this question we modified the Laursen 
method [7] of Edman degradation ofpeptides bound 
to insoluble supports for direct formation of pure 
phenylthiohydantoines (PTHs) [8], which, without 
chemical manipulations, are directly separated and 
quantitatively identified by high pressure liquid 
chromatography (HPLC) [9,10]. Independently from 
the sometimes misleading results from amino acid 
analysis after total hydrolysis of support-bound 
peptides our modification permits to detect quanti- 
tatively < 0.5% of sequential inhomogeneities n 
peptides ynthetized on insoluble polymers and still 
attached to the support. 
* Part of diploma work (1975) Heidelberg, [1]. 
Peptide Synthesizer (Schwarz/Man, Orangeburg, 
N.Y., USA) equipped with the centrifugal reactor 
[11] (LKB Instruments, Munich, FRG) Synthesis 
control system [3] (SCS): Centrifugal reactor, 
Uvicord Ili (LKB Instruments, Munich), 3-Channel 
recorder with automatic 15-times cale expansion 
and integrator (Linseis, Selb, FRG). UV spectro- 
photometer DB-G and Amino acid analyzer Unichrom 
C (Beckman, Munich), Sequemat (Sequemat Inc., 
Watertown, Mass., USA), modified for direct PTH 
conversion [8]. HPLC-System (DuPont 830, Friedberg, 
FRG); Spectroflow SF770 (Schoeffel, Trappenkamp, 
FRG) technical data see preceding paper [9] ; Ddz**- 
hydrazide and some of the Ddz-amino acids were 
purchased from C. H. Boehringer Sohn (Ingelheim, 
FRG) and used analytically pure. All reagents and 
solvents both for solid phase peptide synthesis and 
Edman degradation were purified as published [5,8]. 
3. Methods 
Starting from 1 g of polystyrene gel (< 0.5% 
DVB) esterified [12] with 0.250 mmol Ddz -Thr (But), 
the Merrifield synthesis of sequence B 22-30 (human 
** Abreviations: Ddz-a,~-Dimethyl-3,5-dimethoxybenzyloxy- 
carbonyl-([ 12], acid-sensitive protecting group); DVB: 
divinylbenzene (cross-linking a ent); DCC: dicyclohexyl- 
carbodiimide; NPA: 3-nitrophthalic anhydride (blocking 
agent for suppression f failure sequences). 
68 North-Holland Publishing Company - Amsterdam 
Volume 55, number 1 FEBS LETTERS July 1975 
Tyr 
Pro 
l I I I I ! I I I I I I I I I I I 
Time (rain) 15 10 5 
stage of 
degradation 
Nn 
1 
- -F ; -  
------13- 
16 
18 
19 
I 
I I 
0 
Fig. 1. HPL chromatogram of the PTH pattern from solid phase degradation of the nonapeptide B22-30 (Human Insulin) 
synthetized on solid phase. (Thr*: PTH-dehydro-Thr) 
insulin) was performed in the centrifugal reactor 
utilizing three times a five-fold excess of Ddz-amino 
acid and DCC in 90 ml dichloromethane (total 
volume) at each stage of the synthesis. All operations, 
including NPA treatment [14], were programmed as 
published [5] and monitored by SCS [3]. Incorpo- 
ration of Ddz-amino acids (mmol/g starting polymer) 
[5] during hexapeptide synthesis: 0.250 Thr(But); 
0.251 Lys(Z); 0.250 Pro; 0.241 Thr(But); 0.260 Tyr 
(But); 0.245 Phe. 
40 mg of gel polymer supporting the hexapeptide 
(I) was taken out of the reactor for intermediate 
control of the synthesis by solid phase Edman degra- 
dation. Finally, the synthesis yielded 1.32 ~ of 
polymer supported fully protected nonapeptide. Ddz- 
Arg(Tos)-Gly-Phe-Phe-Tyr(But)-Thr(But)-Pro  
Lys(Z)-Thr(But)-O-polystyrene gel phase (II). I0 
mg of protected nonapeptide on polymer were hydro- 
lyzed in a sealed vial with conc. HC1/propionic acid 
1:1 (v,v) for 15 min at 160°C [15] and analyzed 
(theor. values in brackets) Arg 1.01 (1); Gly 1.00 
(1); Phe 1.82 (2); Thr 1.82 (2); Pro 1.17 (1); Tyr 
0.73 (1); Lys 1.29 (1). 7.25 mg of I and 8.70 mg of 
t Not corrected for mechanical losses from tests and emptying 
of the reactor. 
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I1 for control of sequential uniformity were degraded 
by the Laursen method [7] as described in the preced- 
ing papers [8,9]. To charge the column of the 
Sequemat apparatus with stationary solid phase [5], 
samples 1and 1I, respectively, were mixed with glass 
beads (960 mg each; 200-400 mesh). The operations 
for degradation i cluding direct conversion to PTH- 
amino acids were programmed as described [8]. The 
HPLC analyses of the PTHs obtained were performed 
as demonstrated in the preceding communication [9]. 
hydroxyl side functions on Tyr B26, Thr B27, and 
Thr B30. In addition we measured an average cleavage 
of 10% of the peptide ester bond to its support by 
trifluoroacetic acid per stage of degradation. This 
partly explains the 20% lowered efficiency of the 
degradation/stage, which is effected mainly by 
insufficient solvation of the insolubilized peptide on 
polymer support. 
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4. Results and discussion 
The HPLC elution diagrams only from degradation 
of II are summarized and evaluated in fig.1 and table 1, 
respectively, to show the main essentials. Except for 
the content of 1.5% of the octapeptide B 23-30 (not 
acylated by Ddz-Arg(Tos) B22 in the last step of the 
Merrifield synthesis) the final nonapeptide is not 
contaminated by any other truncated [4] sequence 
(see first stage of degradation, fig. 1). Besides the main 
sequence, an octapeptide that lacks Gly B23 can be 
detected at a level of 2% (failure [4] sequence; see 
second and subsequent s ages of degradation, fig. 1). 
These two subsequences characterize a synthetic 
inhomogenity of 3.5 -+ 0.5% [9] of the desired nona- 
peptide, which therefore is of 96.5% uniformity. The 
result fits very well with data from measurement of
incorporation of Ddz-amino acids (98% Ddz-Phe B25) 
and from amino acid analysis (see Methods); the 
continuous SCS showed no significant drop in the 
recording of the transformations during Merrifield 
synthesis. 
Shorter sequences degraded (stage 3 -8 )  most 
probably are the consequence of peptide fission by 
trifluoroacetic acid action (45°C) during degradation, 
accelerated by anchimeric affects from deprotected 
This work was supported by the Deutsche Forschungs- 
gemeinschaft. 
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